The level of TRFLeuCAG in human NSCLC tumour tissues was higher than that in normal tissues, and inhibition of TRF LeuCAG in H1299 cells inhibited cell proliferation, indicating that TRF LeuCAG can serve as a therapeutic target for NSCLC [26]. Here, TERF1 is linked to neoplasm.